Biovaxys Technol Stock Price, News & Analysis

Welcome to our dedicated page for Biovaxys Technol news (Ticker: BVAXF), a resource for investors and traders seeking the latest updates and insights on Biovaxys Technol stock.

BioVaxys Technology Corp. (OTCQB: BVAXF) is a clinical-stage biopharmaceutical company whose news flow centers on its DPX™ immune-educating platform, oncology vaccine programs, and licensing activities. Company releases describe DPX as a non-systemic antigen delivery technology used to generate targeted and persistent immune responses, with applications in cancer, infectious disease, and antigen desensitization.

Investors following BVAXF news can expect updates on clinical studies of maveropepimut-S (MVP-S) in advanced relapsed-refractory diffuse large B cell lymphoma and platinum-resistant ovarian cancer, as well as early-stage work in non-muscle invasive bladder cancer and HR+/HER2- breast cancer. News items also highlight DPX+SurMAGE, a dual-targeted immunotherapy for bladder cancer, and DPX-based vaccines such as DPX-RSV and DPX+rPA for anthrax.

BioVaxys regularly reports on collaborations and licensing agreements that leverage its lipid-based technologies. Examples include licensing to SpayVac-for-Wildlife, Inc. for single-dose immunocontraceptive vaccines in wildlife and aquaculture, and to Zoetis Inc. for animal health applications. The company also issues updates on research collaborations, such as combining DPX with Sona Nanotech’s Targeted Hyperthermia Therapy™ and exploring DPX as a carrier for mRNA vaccines.

In addition to scientific and clinical developments, BVAXF news covers corporate actions such as amendments to its asset purchase agreement for the DPX portfolio, share consolidation on the Canadian Securities Exchange, and financing-related milestones. For readers tracking BVAXF, this news page aggregates these disclosures so they can monitor progress of the DPX platform, pipeline evolution, and key partnership developments over time.